drugset / Trial / NCT02328118

25-Gauge Vitrectomy With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in China

NCT02328118

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Proliferative diabetic retinopathy(PDR) is the leading cause of visual loss in diabetic patients. Operation is an efficient method to treat PDR. Anti-vascular endothelial growth factor (anti-VEGF) can be used as an adjuvant therapy which can make operation more easy.

Timeline

Start
2015-02
Primary completion
2017-03
Completion
2017-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranibizumab Monoclonal antibody 0.5 mg Intravitreal
Subject Triamcinolone Acetonide Other / unclassified 4 mg Intravitreal